PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
| 出版年: | HemaSphere |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Wiley
2022-06-01
|
| オンライン･アクセス: | http://journals.lww.com/10.1097/01.HS9.0000850304.03677.28 |
| _version_ | 1850052116088881152 |
|---|---|
| author | A. R. Mato W. G. Wierda J. M. Pagel M. S. Davids P. L. Zinzani Y. Lu H. Liu S. Shahda C. C. Leow C. S. Tam J. A. Woyach T. A. Eyre |
| author_facet | A. R. Mato W. G. Wierda J. M. Pagel M. S. Davids P. L. Zinzani Y. Lu H. Liu S. Shahda C. C. Leow C. S. Tam J. A. Woyach T. A. Eyre |
| author_sort | A. R. Mato |
| collection | DOAJ |
| container_title | HemaSphere |
| format | Article |
| id | doaj-art-c78552d021a442568ce7eee2bb1d7548 |
| institution | Directory of Open Access Journals |
| issn | 2572-9241 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| spelling | doaj-art-c78552d021a442568ce7eee2bb1d75482025-08-20T00:26:18ZengWileyHemaSphere2572-92412022-06-0161743174410.1097/01.HS9.0000850304.03677.28202206003-01743PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)A. R. Mato0W. G. Wierda1J. M. Pagel2M. S. Davids3P. L. Zinzani4Y. Lu5H. Liu6S. Shahda7C. C. Leow8C. S. Tam9J. A. Woyach10T. A. Eyre111 Memorial Sloan Kettering Cancer Center, New York2 University of Texas MD Anderson Cancer Center, Houston3 Loxo Oncology at Lilly, Stamford4 Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America5 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy6 Elli Lily and Company, Indianapolis, United States of America3 Loxo Oncology at Lilly, Stamford3 Loxo Oncology at Lilly, Stamford3 Loxo Oncology at Lilly, Stamford7 Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia8 The Ohio State University Comprehensive Cancer Center, Columbus, United States of America9 Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdomhttp://journals.lww.com/10.1097/01.HS9.0000850304.03677.28 |
| spellingShingle | A. R. Mato W. G. Wierda J. M. Pagel M. S. Davids P. L. Zinzani Y. Lu H. Liu S. Shahda C. C. Leow C. S. Tam J. A. Woyach T. A. Eyre PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS) |
| title | PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_full | PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_fullStr | PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_full_unstemmed | PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_short | PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_sort | pb1863 bruin cll 322 a phase 3 open label randomized study of fixed duration pirtobrutinib venetoclax and rituximab vs venetoclax and rituximab in previously treated cll sll trial in progress |
| url | http://journals.lww.com/10.1097/01.HS9.0000850304.03677.28 |
| work_keys_str_mv | AT armato pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT wgwierda pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT jmpagel pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT msdavids pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT plzinzani pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT ylu pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT hliu pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT sshahda pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT ccleow pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT cstam pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT jawoyach pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress AT taeyre pb1863bruincll322aphase3openlabelrandomizedstudyoffixeddurationpirtobrutinibvenetoclaxandrituximabvsvenetoclaxandrituximabinpreviouslytreatedcllslltrialinprogress |